TriangleFOR PATIENTS · SOURCE READING
The treatment of gestational trophoblastic neoplasia is based on the type of disease, stage, or risk group.
Source: Gestational Trophoblastic Disease Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2022 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Invasive moles and choriocarcinomas are treated based on risk groups. The stage of the invasive mole or choriocarcinoma is one factor used to determine risk group. Other factors include the following:
Source links and citations
The age of the patient when the diagnosis is made.
Source links and citations
Whether the GTN occurred after a molar pregnancy, miscarriage, or normal pregnancy.
Source links and citations
How soon the tumor was diagnosed after the pregnancy began.
The level of beta human chorionic gonadotropin (beta-hCG) in the blood.
Source links and citations
The size of the largest tumor.
Where the tumor has spread to and the number of tumors in the body.
How many chemotherapy drugs the tumor has been treated with (for recurrent or resistant tumors).
Source links and citations
There are two risk groups for invasive moles and choriocarcinomas: low risk and high risk. Patients with low-risk disease usually receive less aggressive treatment than patients with high-risk disease.
Source links and citations
Placental-site trophoblastic tumor (PSTT) and epithelioid trophoblastic tumor (ETT) treatments depend on the stage of disease.
Preserved source evidence · Independent clinical review pending · Not medical advice